vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and MAXCYTE, INC. (MXCT). Click either name above to swap in a different company.
MAXCYTE, INC. is the larger business by last-quarter revenue ($4.8M vs $3.9M, roughly 1.2× Opus Genetics, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -20.9%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -7.4%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
IRD vs MXCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.8M |
| Net Profit | — | $-9.6M |
| Gross Margin | — | — |
| Operating Margin | — | -234.5% |
| Net Margin | — | -200.5% |
| Revenue YoY | -10.2% | -20.9% |
| Net Profit YoY | 53.0% | 9.4% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.8M | ||
| Q3 25 | $3.1M | $4.6M | ||
| Q2 25 | $2.9M | $5.8M | ||
| Q1 25 | $4.4M | $5.7M | ||
| Q4 24 | $4.3M | $6.1M | ||
| Q3 24 | $3.9M | $5.6M | ||
| Q2 24 | $1.1M | $5.0M | ||
| Q1 24 | $1.7M | $5.6M |
| Q4 25 | — | $-9.6M | ||
| Q3 25 | $-17.5M | $-12.4M | ||
| Q2 25 | $-7.4M | $-12.4M | ||
| Q1 25 | $-8.2M | $-10.3M | ||
| Q4 24 | — | $-10.6M | ||
| Q3 24 | $-7.5M | $-11.6M | ||
| Q2 24 | $-7.8M | $-9.4M | ||
| Q1 24 | $-7.1M | $-9.5M |
| Q4 25 | — | -234.5% | ||
| Q3 25 | -269.9% | -307.4% | ||
| Q2 25 | -309.0% | -244.3% | ||
| Q1 25 | -227.2% | -214.1% | ||
| Q4 24 | — | -213.1% | ||
| Q3 24 | -207.1% | -250.4% | ||
| Q2 24 | -748.9% | -241.0% | ||
| Q1 24 | -450.5% | -219.8% |
| Q4 25 | — | -200.5% | ||
| Q3 25 | -566.9% | -269.7% | ||
| Q2 25 | -257.5% | -212.2% | ||
| Q1 25 | -187.5% | -178.7% | ||
| Q4 24 | — | -175.0% | ||
| Q3 24 | -194.6% | -205.9% | ||
| Q2 24 | -698.3% | -188.8% | ||
| Q1 24 | -415.3% | -170.6% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.25 | $-0.12 | ||
| Q2 25 | $-0.12 | $-0.12 | ||
| Q1 25 | $-0.24 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.29 | $-0.11 | ||
| Q2 24 | $-0.30 | $-0.09 | ||
| Q1 24 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.3M | $171.5M |
| Total Assets | $50.2M | $202.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $103.0M | ||
| Q3 25 | $30.8M | $105.7M | ||
| Q2 25 | $32.4M | $126.6M | ||
| Q1 25 | $41.8M | $138.3M | ||
| Q4 24 | $30.3M | $154.5M | ||
| Q3 24 | $36.6M | $153.8M | ||
| Q2 24 | $41.4M | $157.3M | ||
| Q1 24 | $47.2M | $157.5M |
| Q4 25 | $15.3M | $171.5M | ||
| Q3 25 | $6.0M | $180.3M | ||
| Q2 25 | $17.5M | $190.7M | ||
| Q1 25 | $5.1M | $199.4M | ||
| Q4 24 | $6.7M | $206.3M | ||
| Q3 24 | $34.3M | $213.3M | ||
| Q2 24 | $40.6M | $221.3M | ||
| Q1 24 | $46.1M | $226.4M |
| Q4 25 | $50.2M | $202.5M | ||
| Q3 25 | $36.1M | $213.5M | ||
| Q2 25 | $38.7M | $219.8M | ||
| Q1 25 | $48.2M | $230.0M | ||
| Q4 24 | $36.9M | $239.5M | ||
| Q3 24 | $40.4M | $248.6M | ||
| Q2 24 | $44.8M | $251.5M | ||
| Q1 24 | $51.8M | $257.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-2.7M |
| Free Cash FlowOCF − Capex | — | $-2.9M |
| FCF MarginFCF / Revenue | — | -61.0% |
| Capex IntensityCapex / Revenue | — | 4.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-36.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-2.7M | ||
| Q3 25 | $-6.2M | $-7.5M | ||
| Q2 25 | $-10.3M | $-9.9M | ||
| Q1 25 | $-9.0M | $-14.4M | ||
| Q4 24 | $-25.6M | $-7.8M | ||
| Q3 24 | $-5.1M | $-4.4M | ||
| Q2 24 | $-7.3M | $-4.8M | ||
| Q1 24 | $-5.7M | $-10.6M |
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $-7.8M | ||
| Q2 25 | — | $-10.4M | ||
| Q1 25 | — | $-15.1M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $-4.8M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-11.4M |
| Q4 25 | — | -61.0% | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -179.2% | ||
| Q1 25 | — | -262.3% | ||
| Q4 24 | — | -131.6% | ||
| Q3 24 | — | -85.5% | ||
| Q2 24 | — | -103.3% | ||
| Q1 24 | — | -203.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 6.5% | ||
| Q2 25 | — | 10.0% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 14.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRD
Segment breakdown not available.
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
